WO2007133730A3 - Materials and methods for control of infections - Google Patents

Materials and methods for control of infections Download PDF

Info

Publication number
WO2007133730A3
WO2007133730A3 PCT/US2007/011519 US2007011519W WO2007133730A3 WO 2007133730 A3 WO2007133730 A3 WO 2007133730A3 US 2007011519 W US2007011519 W US 2007011519W WO 2007133730 A3 WO2007133730 A3 WO 2007133730A3
Authority
WO
WIPO (PCT)
Prior art keywords
provides
vector
another aspect
subject
antimicrobial peptide
Prior art date
Application number
PCT/US2007/011519
Other languages
French (fr)
Other versions
WO2007133730A2 (en
Inventor
Nasser Chegini
Xiaoping Luo
Qun Pan
Lung-Ji Chang
Original Assignee
Univ Florida
Nasser Chegini
Xiaoping Luo
Qun Pan
Lung-Ji Chang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Florida, Nasser Chegini, Xiaoping Luo, Qun Pan, Lung-Ji Chang filed Critical Univ Florida
Publication of WO2007133730A2 publication Critical patent/WO2007133730A2/en
Publication of WO2007133730A3 publication Critical patent/WO2007133730A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/13—Tumour cells, irrespective of tissue of origin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor

Abstract

The subject invention provides materials and methods for providing immediate and long-term protection against pathogenic microorganisms. One aspect of the subject invention provides a vector, such as a lentiviral vector carrying a nucleic acid sequence encoding an antimicrobial peptide, such as dermcidin (DCD), as an efficient means of delivery of the peptide. Preferably, the vector has a tetracycline-dependent transcriptional regulatory system such that expression of the nucleic acid sequence encoding the antimicrobial peptide is effectively turned 'off' in the absence of tetracycline or its derivatives. Another aspect of the invention provides host cells that have been genetically modified with a vector of the invention to produce an antimicrobial peptide. Another aspect of the invention provides compositions comprising the vectors or host cells of the invention and a pharmaceutically acceptable carrier. Another aspect of the subject invention provides a method for treating or inhibiting the growth of a pathogenic microorganism by administering a vector or host cell of the invention to a subject suffering from, or susceptible to, infection by the pathogenic microorganism. Another aspect of the subject invention provides a method for detecting the presence of an antimicrobial peptide, such as DCD, within a male or female subject's urogenital tract.
PCT/US2007/011519 2006-05-11 2007-05-11 Materials and methods for control of infections WO2007133730A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US79956906P 2006-05-11 2006-05-11
US60/799,569 2006-05-11

Publications (2)

Publication Number Publication Date
WO2007133730A2 WO2007133730A2 (en) 2007-11-22
WO2007133730A3 true WO2007133730A3 (en) 2008-01-17

Family

ID=38694519

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/011519 WO2007133730A2 (en) 2006-05-11 2007-05-11 Materials and methods for control of infections

Country Status (1)

Country Link
WO (1) WO2007133730A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8329865B2 (en) * 2001-06-13 2012-12-11 Eberhard-Karls-Univresitaet Tuebingen Universitaetsklinikum Antimicrobially active peptides
EP3360891B1 (en) 2017-02-14 2022-03-30 Karlsruher Institut für Technologie Cell penetrating peptides of human origin
ES2880043A1 (en) * 2020-05-20 2021-11-23 Fundacion Para El Fomento De La Investig Sanitaria Y Biomedica De La Comunitat Valenciana Fisabio PEPTIDE FOR USE IN THE PREVENTION AND/OR TREATMENT OF A DISEASE CAUSED BY A VIRUS THAT AFFECTS THE RESPIRATORY TRACT (Machine-translation by Google Translate, not legally binding)
EP4183406A1 (en) * 2021-11-19 2023-05-24 Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO) In vitro methods and kits for respiratory tract viral diseases

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030148945A1 (en) * 2001-08-24 2003-08-07 Micrologix Biotech Inc. Antimicrobial and anti-inflammatory peptides
US6906035B2 (en) * 1995-06-02 2005-06-14 The University Of British Columbia Antimicrobial cationic peptides

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6906035B2 (en) * 1995-06-02 2005-06-14 The University Of British Columbia Antimicrobial cationic peptides
US20030148945A1 (en) * 2001-08-24 2003-08-07 Micrologix Biotech Inc. Antimicrobial and anti-inflammatory peptides

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LIAO ET AL.: "Cationic peptide of the male reproductive tract, HE2a, displays antimicrobial activity against Neisseria gonorrhoeae, Staphylococcus aureus and Enterococcus faecalis", JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, vol. 56, September 2005 (2005-09-01), pages 957 - 961 *

Also Published As

Publication number Publication date
WO2007133730A2 (en) 2007-11-22

Similar Documents

Publication Publication Date Title
Gaca et al. Adaptation to adversity: the intermingling of stress tolerance and pathogenesis in enterococci
Mahamoud et al. Quinoline derivatives as promising inhibitors of antibiotic efflux pump in multidrug resistant Enterobacter aerogenes isolates
Itzek et al. Hydrogen peroxide-dependent DNA release and transfer of antibiotic resistance genes in Streptococcus gordonii
Xiong et al. Biological control of microbial attachment: a promising alternative for mitigating membrane biofouling
Scott et al. The life and death of Helicobacter pylori
Henry et al. Oxidative stress resistance in Porphyromonas gingivalis
Kint et al. The alternative sigma factor σB plays a crucial role in adaptive strategies of Clostridium difficile during gut infection
Daly et al. MCR-1 inhibition with peptide-conjugated phosphorodiamidate morpholino oligomers restores sensitivity to polymyxin in Escherichia coli
RU2529799C2 (en) Compositions for enhancing antibacterial activity of myeloperoxidase and methods of their application
Krumbeck et al. Characterization of the ecological role of genes mediating acid resistance in L actobacillus reuteri during colonization of the gastrointestinal tract
Stanton et al. Collateral effects of antibiotics: carbadox and metronidazole induce VSH-1 and facilitate gene transfer among Brachyspira hyodysenteriae strains
Biswas et al. Molecular mechanisms of Staphylococcus and Pseudomonas interactions in cystic fibrosis
Ge et al. Effect of acetic acid on bacteriocin production by gram-positive
MXPA04000192A (en) Composition having bacteristatic and bactericidal activity against bacterial spores and vegetative cells and process for treating foods therewith.
Dione et al. The aerobic activity of metronidazole against anaerobic bacteria
Slany et al. Formation of Staphylococcus aureus biofilm in the presence of sublethal concentrations of disinfectants studied via a transcriptomic analysis using transcriptome sequencing (RNA-seq)
Yu et al. Global transcriptional response of Staphylococcus aureus to rhein, a natural plant product
WO2007133730A3 (en) Materials and methods for control of infections
TW200716162A (en) Use of bovine lactoferrin in the manufacture of a medicament for inhibiting the growth of bacteria
Pandey et al. Probiotic Escherichia coli CFR 16 producing pyrroloquinoline quinone (PQQ) ameliorates 1, 2-dimethylhydrazine-induced oxidative damage in colon and liver of rats
Yoshikawa et al. Korormicin, an antibiotic specific for gram-negative marine bacteria, strongly inhibits the respiratory chain-linked Na+-translocating NADH: quinone reductase from the marine Vibrio alginolyticus
Booth et al. Edwardsiella ictaluri encodes an acid-activated urease that is required for intracellular replication in channel catfish (Ictalurus punctatus) macrophages
Wille et al. Does the mode of dispersion determine the properties of dispersed Pseudomonas aeruginosa biofilm cells?
EP1169480A4 (en) Tissue-specific and pathogen-specific toxic agents and ribozymes
Harrison et al. Overlapping and complementary oxidative stress defense mechanisms in nontypeable Haemophilus influenzae

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07809077

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07809077

Country of ref document: EP

Kind code of ref document: A2